Long-acting medications for the hyperkinetic disorders

@article{Schlander2007LongactingMF,
  title={Long-acting medications for the hyperkinetic disorders},
  author={Michael Schlander},
  journal={European Child \& Adolescent Psychiatry},
  year={2007},
  volume={16},
  pages={421-429}
}
  • M. Schlander
  • Published 30 March 2007
  • Medicine, Psychology
  • European Child & Adolescent Psychiatry
New long-acting medications for attention-deficit/hyperactivity disorder (ADHD) have become available, which combine certain advantages over conventional short-acting drugs with higher acquisition costs. Choices between these drugs should thus be driven by their clinical profiles and by an acceptable balance of increased costs and additional benefits. Accordingly, the notion of relative cost-effectiveness should be central to recommendations about the use of these drugs in practice. A recent… 
[The health economics of attention deficit hyperactivity disorder in Germany. Part 2: Therapeutic options and their cost-effectiveness].
TLDR
International evaluations indicate an acceptable to attractive cost-effectiveness--according to currently used international benchmarks--of an intense medication management strategy based on stimulants, primarily methylphenidate, with ICERs ranging from 20,000 Euros to 37,000 EUR per quality-adjusted life year (QALY) gained.
European guidelines on managing adverse effects of medication for ADHD
TLDR
A guidelines group of the European Network for Hyperkinetic Disorders (EUNETHYDIS) has reviewed the literature, recruited renowned clinical subspecialists and consulted as a group to examine concerns about the safety of ADHD medications.
Attention-Deficit Hyperactivity Disorder
TLDR
The efficacy and safety of five of the more novel long-acting pharmacological treatments recently approved by the FDA for marketing in the US for paediatric ADHD, along with an α2-adrenoceptor agonist in preparation are considered.
Stimulant drug effects on attention deficit/hyperactivity disorder: a review of the effects of age and sex of patients.
OBJECTIVE As dopamine functioning varies by sex and age it might be expected that the effects of methylphenidate or amfetamine, the psychostimulants used for the treatment of Attention Deficit
Naturalistic-observational studies in the framework of ADHD health care
TLDR
The articles of this supplement represent the first inventory-driven and systematically gathered information of routine patient care in children with symptoms of ADHD in Europe, which may help to improve the quality of provision in the future.
The NICE ADHD health technology assessment: A review and critique
  • M. Schlander
  • Medicine, Psychology
    Child and adolescent psychiatry and mental health
  • 2008
TLDR
There remains a need for a new, state-of-the-art systematic review of ADHD treatment strategies including economic evaluation, which ideally should address outcomes beyond children's health-related quality of life, such as long-term sequelae of the disorder and caregiver burden.
Reboxetine versus methylphenidate in treatment of children and adolescents with attention deficit-hyperactivity disorder
TLDR
It is revealed that reboxetine may be beneficial in treatment of ADHD and further studies are required to clarify the potential therapeutic effects on comorbid depression and anxiety and adverse effect profile.
Co-existence of tic disorders and attention-deficit/hyperactivity disorder-recent advances in understanding and treatment
TLDR
This editorial gives a short overview of the essential research topics concerning TD + ADHD and shows where (in this ECAP supplement and other literature) empirically based answers can be found.
Impact of Attention-Deficit/Hyperactivity Disorder (ADHD) on prescription dug spending for children and adolescents: increasing relevance of health economic evidence
  • M. Schlander
  • Medicine, Political Science
    Child and adolescent psychiatry and mental health
  • 2007
TLDR
A more than six-fold increase of pharmaceutical spending for children and adolescents is predicted over the decade from 2002 to 2012, from the perspectives of both the NHS in England and the GKV in Germany.
Change in the direct cost of treatment for children and adolescents with hyperkinetic disorder in Germany over a period of four years
TLDR
The direct cost of treatment for hyperkinetic disorder in the age group < 15 years increased considerably between 2002 and 2006, and expenditure for epilepsy and asthma was more or less constant.
...
...

References

SHOWING 1-10 OF 69 REFERENCES
Long-acting medications for the hyperkinetic disorders
A systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorder is reported, giving effect sizes and numbers-to-treat for
Effectiveness outcomes in attention-deficit/hyperactivity disorder.
TLDR
The methodology needed to demonstrate empirically the impact of treatment on actual burden of illness in practice is discussed and measures of effectiveness empirically are explored.
Cost effectiveness of methylphenidate versus AMP/DEX mixed salts for the first-line treatment of ADHD
  • S. Narayan, J. Hay
  • Psychology, Medicine
    Expert review of pharmacoeconomics & outcomes research
  • 2004
TLDR
The cost effectiveness in choosing methylphenidate or amphetamine/ dextroamphetamine mixed salts (Adderall) as a first-line agent in the treatment of attention deficit hyperactivity disorder is evaluated.
Compliance with Stimulants for Attention-Deficit/Hyperactivity Disorder
TLDR
Improved provision of education and information for individuals with ADHD, as well as their families and teachers, should help them address the issues surrounding stimulant medication and allow full participation in the treatment process.
Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis.
Treatment for ADHD: is more complex treatment cost-effective for more complex cases?
TLDR
Analyses of costs and effectiveness of treatment for ADHD must consider the role of comorbidities, and high-quality MedMgt appears likely to be cost-effective at all levels of willingness to pay.
Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment.
  • M. Lage, P. Hwang
  • Medicine, Psychology
    Journal of child and adolescent psychopharmacology
  • 2004
TLDR
These data support the use of XR MPH with its simplified dosing regimen for children with ADHD, and suggest that once-daily Concerta extended-release methylphenidate is associated with better compliance, decreased likelihood of accidents, and lower health-care resource use over a 1-year period.
Attention-Deficit Hyperactivity Disorder: Critical Appraisal of Extended Treatment Studies
TLDR
A systematic review of the literature on the long-term treatment of attention-deficit hyperactivity disorder found that Rigorous treatment research among representative samples of ADHD individuals is needed.
Is NICE infallible? A qualitative study of its assessment of treatments for attention-deficit/hyperactivity disorder (ADHD)
TLDR
The present qualitative case study of one assessment suggests that the NICE assessment of ADHD treatment strategies was incomplete and likely prone to bias, and NICE did not adequately accommodate a complex clinical decision problem.
...
...